Feasibility of a Wireless Thermal Capsule Endoscopy to Detect Gastrointestinal Thermal Variance

Exclusion Criteria18

• Participant is older than 75 years of age
• Participant with current dysphagia or any swallowing disorder
• Participant with any current condition believed to have an increased risk of capsule retention such as gastrointestinal strictures, intestinal tumors, bowel obstruction, incomplete colonoscopies or fistula
• Participant with a diagnosis of gastroparesis or small bowel or large bowel dysmotility
• Participant with a history of inflammatory bowel disease (IBD), intestinal Crohn's disease, chronic constipation, or rectal bleeding
• Participant with clinical evidence of renal disease, including clinically significant laboratory abnormalities of renal function within the past 6 months
• Participant with chronic usage of nonsteroidal anti-inflammatory drugs (NSAIDs)
• Participants with a known contradiction to metoclopramide
• Participants with a known contraindication to polyethylene glycol
• Participant with currently suspected or diagnosed with hematochezia, melena, iron deficiency with or without anemia
• Participant who has had intestinal surgery in the past
• Participant with a history of congestive heart failure
• Participant with Type I or Type II Diabetes
• Participant has a cardiac pacemaker or other implanted electromedical device.
• Participant expected to undergo MRI examination within 7 days after ingestion of the capsule.
• Participant has participated in an investigational drug or device research study within 30 days of enrollment that may interfere with the subject's safety or ability to participate in this study
• Participant with delayed gastric emptying
• Participant who is pregnant, suspected pregnant, or is actively breast-feeding.